Innovative Medicines
Our focus is to develop and deliver Innovative Medicinesthat address unmet medical needs and improve the standard of care for our patients.
Sun Pharma has invested heavily to expand its Innovative Medicines product portfolio, advance a robust pipeline of clinical-stage assets and identify key partnership opportunities to support continued growth.
Sun Pharma’s portfolio of Innovative Medicines offers targeted treatment options trusted by healthcare professionals and patients.
Sun Pharma dedicates approximately 10% of its annual Innovative Medicines revenue toward R&D of Innovative Medicines.
Therapeutic Areas
At Sun Pharma, we are driven by promising science that has the potential to transform the lives of patients in the U.S. As we continue to expand our product portfolio and clinical pipeline, we actively seek innovative partnerships that complement our expertise and accelerate the development of medicines in these key focus areas:
Immunology
- Acne
- Alopecia Areata
- Psoriasis
- IL-23 Inhibitor
- JAK Inhibitor
Ophthalmology
- Dry Eye
- Post Op Inflammation
- Ocular Hypertension
- Glaucoma
Oncology
- Actinic Keratosis
- Locally Advanced Basal Cell Carcinoma
- Cutaneous Squamous Cell Carcinoma
- Metastatic Castration-Resistant Prostate Cancer
- Non-melanoma skin cancers
Metabolics
- Type 2 Diabetes
- Obesity
R&D Pipeline
We are accelerating innovation to build a science-driven clinical-stage pipeline of transformative therapies. We are committed to indication expansion and evidence generation, providing clinicians and patients with the real-world and clinical data needed to make informed treatment decisions.
| Candidate | Mechanism of Action | Indication | Preclinical | Phase-1 | Phase-2 | Phase-3 | Registration |
|---|---|---|---|---|---|---|---|
| Ilumya (tildrakizumab) | IL-23 Antagonist | Psoriasis |
|
||||
| Psoriasis – Pediatric |
|
||||||
| Scalp Psoriasis |
|
||||||
| Nail Psoriasis |
|
||||||
| Genital Psoriasis |
|
||||||
| Nidlegy™ | Immunocytokines | Melanoma & non-melanoma skin cancers |
|
||||
| MM-II | Liposomal intra-articular lubrication | Pain in osteoarthritis |
|
||||
| Fibromun | Soft tissue sarcomas |
|
|||||
| Glioblastoma |
|
||||||
| GLO034 | GLP-1R Agonist | Type 2 diabetes & obesity |
|
||||
Clinical Trials
Sun Pharma is committed to advancing medical research through clinical trials, offering eligible patients access to investigational treatments. Participants must meet study-specific criteria.
Contact us at [email protected] or call 1-833-786-4636 to explore available clinical trials. Your participation could make a difference.
Expanded Access
Sun Pharma’s Expanded Access policy allows seriously ill patients without treatment options to access investigational products outside clinical trials, subject to local regulations. The product must be under investigation with an acceptable safety profile.
Treating physicians can submit questions or requests regarding expanded access to [email protected] or 1-833-786-4636.
For U.S. healthcare professionals seeking additional information about Sun Pharma products, grants and other medical information, visit www.sunpharmamedical.com
Collaborate with us
Partnering with Sun Pharma means joining forces with a global pharmaceutical leader committed to investing in innovation and delivering impactful treatments for people in the U.S. and around the world. Our investments in advancing our U.S. Innovative Medicines portfolio revolve around three core strategies:
- Strategic partnerships: We aim to expand our emerging product portfolio by securing access through in-licensing agreements and strategic acquisitions.
- Clinical development: We are committed to advancing our pipeline of Innovative Medicine assets through rigorous clinical development, leveraging our in-house R&D capabilities and established relationships with external third-parties.
- Commercial infrastructure: We have established a robust commercial infrastructure to market and distribute our Innovative Medicines, Generics, and Consumer Healthcare products effectively.
Become a Sun Pharma partner today
Contact us if you are interested in partnering with Sun Pharma. Together, we can advance new treatments and meaningfully impact patients’ lives.
For more information about collaborating with us in the U.S., please contact our Business Development team lead:
For more information about partnering with us outside the U.S., please contact our Business Development team lead:
Center of Excellence
Our India Center of Excellence plays a critical role in driving innovation, ensuring cost efficiency, and accelerating drug development—benefiting millions of U.S. patients and healthcare providers. With more than 40 years of history as a pharmaceutical leader in India, Sun Pharma is uniquely positioned to take full advantage of the CoE.
- Global expertise, local execution. India CoE supports drug development projects through India hub, ensuring seamless integration with global operations.
- Innovation hub. India CoE serves as an innovation hub, combining the latest developments in pharmaceutical research with India’s rich scientific talent pool to drive breakthroughs in drug discovery and development.
- Cost efficiency. India CoE offers significant cost advantages without compromising quality, enabling Sun Pharma to optimize resources.
Our REMS programs help maximize treatment benefits while minimizing risks.